Literature DB >> 20927730

Opiate treatment for opiate withdrawal in newborn infants.

David A Osborn1, Heather E Jeffery, Michael J Cole.   

Abstract

BACKGROUND: Neonatal abstinence syndrome (NAS) due to opiate withdrawal may result in disruption of the mother-infant relationship, sleep-wake abnormalities, feeding difficulties, weight loss and seizures.
OBJECTIVES: To assess the effectiveness and safety of using an opiate compared to a sedative or non-pharmacological treatment for treatment of NAS due to withdrawal from opiates. SEARCH STRATEGY: The review was updated in 2010 with additional searches CENTRAL, MEDLINE and EMBASE supplemented by searches of conference abstracts and citation lists of published articles. SELECTION CRITERIA: Randomized or quasi-randomized controlled trials of opiate treatment in infants with NAS born to mothers with opiate dependence. DATA COLLECTION AND ANALYSIS: Each author assessed study quality and extracted data independently. MAIN
RESULTS: Nine studies enrolling 645 infants met inclusion criteria. There were substantial methodological concerns in all studies comparing an opiate with a sedative. Two small studies comparing different opiates were of good methodology.Opiate (morphine) versus supportive care (one study): A reduction in time to regain birth weight and duration of supportive care and a significant increase in hospital stay was noted.Opiate versus phenobarbitone (four studies): Meta-analysis found no significant difference in treatment failure. One study reported opiate treatment resulted in a significant reduction in treatment failure in infants of mothers using only opiates. One study reported a significant reduction in days treatment and admission to the nursery for infants receiving morphine. One study reported a reduction in seizures, of borderline statistical significance, with the use of opiate.Opiate versus diazepam (two studies): Meta-analysis found a significant reduction in treatment failure with the use of opiate.Different opiates (six studies): there is insufficient data to determine safety or efficacy of any specific opiate compared to another opiate. AUTHORS'
CONCLUSIONS: Opiates compared to supportive care may reduce time to regain birth weight and duration of supportive care but increase duration of hospital stay. When compared to phenobarbitone, opiates may reduce the incidence of seizures but there is no evidence of effect on treatment failure. One study reported a reduction in duration of treatment and nursery admission for infants on morphine. Compared to diazepam, opiates reduce the incidence of treatment failure. A post-hoc analysis generates the hypothesis that initial opiate treatment may be restricted to infants of mothers who used opiates only. In view of the methodologic limitations of the included studies the conclusions of this review should be treated with caution.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20927730     DOI: 10.1002/14651858.CD002059.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  30 in total

Review 1.  Treating disorders of the neonatal central nervous system: pharmacokinetic and pharmacodynamic considerations with a focus on antiepileptics.

Authors:  Maria D Donovan; Geraldine B Boylan; Deirdre M Murray; John F Cryan; Brendan T Griffin
Journal:  Br J Clin Pharmacol       Date:  2015-11-04       Impact factor: 4.335

2.  The Pharmacokinetics and Pharmacodynamics of Buprenorphine in Neonatal Abstinence Syndrome.

Authors:  Jason N Moore; Marc R Gastonguay; Chee M Ng; Susan C Adeniyi-Jones; David E Moody; Wenfang B Fang; Michelle E Ehrlich; Walter K Kraft
Journal:  Clin Pharmacol Ther       Date:  2018-04-28       Impact factor: 6.875

3.  Methadone dosing strategies in preterm neonates can be simplified.

Authors:  Tamara van Donge; Samira Samiee-Zafarghandy; Marc Pfister; Gilbert Koch; Majid Kalani; Arash Bordbar; John van den Anker
Journal:  Br J Clin Pharmacol       Date:  2019-04-10       Impact factor: 4.335

4.  Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome.

Authors:  Chee M Ng; Erin Dombrowsky; Hopi Lin; Michelle E Erlich; David E Moody; Jeffrey S Barrett; Walter K Kraft
Journal:  Pharmacotherapy       Date:  2015-07-14       Impact factor: 4.705

5.  Characteristics and quality of life of opioid-dependent pregnant women in Austria.

Authors:  Verena E Metz; Sandra D Comer; Johanna Wuerzl; Anna Pribasnig; Gabriele Fischer
Journal:  Arch Womens Ment Health       Date:  2014-07-15       Impact factor: 3.633

Review 6.  Pharmacological and non-pharmacological treatments for the Neonatal Abstinence Syndrome (NAS).

Authors:  A K Mangat; G M Schmölzer; W K Kraft
Journal:  Semin Fetal Neonatal Med       Date:  2019-02-05       Impact factor: 3.926

7.  Variation in treatment of neonatal abstinence syndrome in US children's hospitals, 2004-2011.

Authors:  S W Patrick; H C Kaplan; M Passarella; M M Davis; S A Lorch
Journal:  J Perinatol       Date:  2014-06-12       Impact factor: 2.521

Review 8.  Pharmacologic management of the opioid neonatal abstinence syndrome.

Authors:  Walter K Kraft; John N van den Anker
Journal:  Pediatr Clin North Am       Date:  2012-08-30       Impact factor: 3.278

Review 9.  Changing mechanisms of opiate tolerance and withdrawal during early development: animal models of the human experience.

Authors:  Gordon A Barr; Anika McPhie-Lalmansingh; Jessica Perez; Michelle Riley
Journal:  ILAR J       Date:  2011

10.  Patterns of opioid utilization in pregnancy in a large cohort of commercial insurance beneficiaries in the United States.

Authors:  Brian T Bateman; Sonia Hernandez-Diaz; James P Rathmell; John D Seeger; Michael Doherty; Michael A Fischer; Krista F Huybrechts
Journal:  Anesthesiology       Date:  2014-05       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.